Dr Reddy's Laboratories Cash on Hand 2012-2026 | RDY
Dr Reddy's Laboratories cash on hand from 2012 to 2026. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Dr Reddy's Laboratories cash on hand for the quarter ending June 30, 2026 was $865M, a 10.05% increase year-over-year.
- Dr Reddy's Laboratories cash on hand for 2026 was $0.938B, a 36.93% increase from 2025.
- Dr Reddy's Laboratories cash on hand for 2025 was $0.685B, a 30.03% decline from 2024.
- Dr Reddy's Laboratories cash on hand for 2024 was $0.979B, a 27.64% increase from 2023.
|
Dr Reddy's Laboratories Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2026 | $938 |
| 2025 | $685 |
| 2024 | $979 |
| 2023 | $767 |
| 2022 | $610 |
| 2021 | $490 |
| 2020 | $356 |
| 2019 | $363 |
| 2018 | $325 |
| 2017 | $284 |
| 2016 | $606 |
| 2015 | $650 |
| 2014 | $568 |
| 2013 | $415 |
| 2012 | $357 |
|
Dr Reddy's Laboratories Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2026-06-30 | $865 |
| 2026-03-31 | $938 |
| 2025-12-31 | $923 |
| 2025-09-30 | $788 |
| 2025-06-30 | $786 |
| 2025-03-31 | $685 |
| 2024-12-31 | $706 |
| 2024-09-30 | $758 |
| 2024-06-30 | $1,141 |
| 2024-03-31 | $979 |
| 2023-12-31 | $877 |
| 2023-09-30 | $827 |
| 2023-06-30 | $756 |
| 2023-03-31 | $767 |
| 2022-12-31 | $589 |
| 2022-09-30 | $346 |
| 2022-06-30 | $439 |
| 2022-03-31 | $610 |
| 2021-12-31 | $497 |
| 2021-09-30 | $347 |
| 2021-06-30 | $394 |
| 2021-03-31 | $490 |
| 2020-12-31 | $243 |
| 2020-09-30 | $354 |
| 2020-06-30 | $371 |
| 2020-03-31 | $356 |
| 2019-12-31 | $286 |
| 2019-09-30 | $411 |
| 2019-06-30 | $392 |
| 2019-03-31 | $363 |
| 2018-12-31 | $365 |
| 2018-09-30 | $272 |
| 2018-06-30 | $232 |
| 2018-03-31 | $325 |
| 2017-12-31 | $350 |
| 2017-09-30 | $260 |
| 2017-06-30 | $231 |
| 2017-03-31 | $284 |
| 2016-12-31 | $298 |
| 2016-09-30 | $323 |
| 2016-06-30 | $380 |
| 2016-03-31 | $606 |
| 2015-12-31 | $577 |
| 2015-09-30 | $523 |
| 2015-06-30 | $561 |
| 2015-03-31 | $650 |
| 2014-12-31 | $118 |
| 2014-09-30 | $471 |
| 2014-06-30 | $548 |
| 2014-03-31 | $568 |
| 2013-12-31 | $507 |
| 2013-09-30 | $442 |
| 2013-06-30 | $505 |
| 2013-03-31 | $415 |
| 2012-12-31 | $435 |
| 2012-09-30 | $410 |
| 2012-06-30 | $384 |
| 2012-03-31 | $357 |
| 2011-12-31 | $349 |
| 2011-09-30 | $192 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $9.749B | $3.580B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |